Skip to main content

Advertisement

Table 1 Patient and tumor characteristics

From: The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer

Factor   Set 1 Set 2 Set 3 Set 4 Set 5 Total
No of patients 169 488 167 291 407 1,522
Events 20 55 39 39 82 235
Patient material I a 30 9 66 39 77 221
Patient material II a 0 0 0 67 99 166
Patient material III a 28 100 5 27 57 217
Patient material IV a 16 109 9 145 100 379
Patient material V a 95 270 87 13 74 539
Age median, years 45 65 53 61 61 60
Age range, years 28-50 50-90 27-93 30-88 33-89 27-93
Tumor size       
  ≤ 20 mm 113 (67)b 364 (75) 68 (41) 115 (40) 208 (51) 868 (57)
  >20 mm 56 (33) 124 (25) 99 (59) 176 (60) 199 (49) 654 (43)
Lymph nodes       
  Negative 169 488 0 291 0 948 (62)
1-3 positive 0 0 167 0 407 574 (38)
ER status       
  Positive 131 (78) 399 (82) 122 (73) 235 (81) 329 (81) 1,216 (80)
  Negative 38 (22) 89 (18) 45 (27) 56 (19) 78 (19) 306 (20)
PgR status       
  Positive 46 (71) 121 (61) 56 (70) 168 (63) 200 (63) 591 (64)
  Negative 19 (29) 76 (39) 24 (30) 100 (37) 118 (37) 337 (36)
  Missing 104 291 87 23 89 594
Histological grade       
  1 41 (24) 136 (28) 19 (11) 32 (11) 67 (17) 295 (20)
  2 82 (49) 250 (51) 97 (58) 166 (57) 233 (57) 828 (54)
  3 46 (27) 102 (21) 51 (31) 93 (32) 107 (26) 399 (26)
Ki67       
  Low 109 (64) 343 (70) 111 (66) 210 (72) 315 (77) 1,088 (71)
  Highc 60 (36) 145 (30) 56 (34) 81 (28) 92 (23) 434 (29)
HER2 status       
  Negative 54 (92) 142 (87) 62 (84) 216 (86) 249 (88) 723 (87)
  Positived 5 (8) 21 (13) 12 (16) 36 (14) 33 (12) 107 (13)
  Missing 110 325 93 39 125 692
Adjuvant endocrine treatment       
  Yes 0 0 0 291 407 698 (46)
  No 169 488 167 0 0 824 (54)
  1. Patient materials I-V were pooled in a database from which the following subsets were extracted: Set 1: node-negative (N0), no adjuvant therapy, ≤50 years at diagnosis, Set 2: N0, no adjuvant therapy, >50 years at diagnosis, Set 3: node-positive (N1), no adjuvant therapy, Set 4: N0, adjuvant endocrine therapy, and Set 5: N1, adjuvant endocrine therapy.
  2. ER = estrogen receptor, PgR = progesterone receptor, HER2 = human epidermal growth factor 2.
  3. aPatient material I (Rydén et al. 2005), Patient material II (Swedish Breast Cancer Cooperative Group 1996; Chebil et al. 2003), Patient material III (Borgquist et al. 2008), Patient material IV (Falck et al. 2012), and Patient material V (Hansen et al. 2000).
  4. bNumbers in parentheses are percentages.
  5. cHigh Ki67 was previously defined as cases above the seventh decile in the empirical Ki67 distribution (which corresponds to 20% positive cells) (Klintman et al. 2010) and 20% was used for Patient materials I-IV. Cases above the median were considered Ki67 high in Patient material V.
  6. dHER2: positive if HER2-IHC 3+ or HER2-IHC 2+ and FISH amplified.